We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Electrochemical Cell-Free Biosensor Directly Detects Influenza Antibodies in Blood at POC

By LabMedica International staff writers
Posted on 18 Jan 2023

The quantitative detection of specific antibodies in complex samples like blood can make it possible to identify several diseases although it generally requires a complicated laboratory procedure. More...

Researchers have now developed a new method for the rapid, inexpensive, yet quantitative and specific point-of-care detection of antibodies. The new method uses an electrochemical cell-free biosensor that can directly detect antibodies against diseases such as influenza in blood serum.

Influenza is a serious, widespread, epidemic disease that can prove fatal as well as create significant societal and economic consequences. This makes the clinical evaluation of immune responses to flu vaccines and infections highly important. A simple, inexpensive, point-of-care diagnostic method is a more suitable alternative to the presently available expensive and complex laboratory analysis. The new method developed by researchers at University of Rome (Rome, Italy) meets this need and is based on “programmable” gene circuits, cell-free transcription, and electrochemical detection.

In living cells, genes are read by RNA polymerases and transcribed into an RNA sequence, which then acts as a blueprint for building proteins. This “machinery” can also be used by cell-free systems. In order to build the new detector, the researchers combined this type of machinery with specifically designed synthetic gene circuits that become “switched on” when the antibody being tested for is present in the sample. As an example, the team designed a test that detects anti-influenza antibodies, which are directed against a surface molecule on influenza viruses. The researchers achieved this by developing a synthetic gene with an incomplete promoter which is a DNA segment that controls the reading of the gene. If the promoter is incomplete, then RNA polymerase cannot begin the RNA transcription.

The test solution also contains a pair of synthetic DNA strands that are bound to a protein portion (also called peptide) that is specifically recognized by anti-influenza antibodies. Upon binding between the antibodies and the peptide, the two DNA strands are arranged in a manner that completes the promoter and switches the synthetic gene on. The RNA polymerase can now dock on the synthetic gene and begin transcribing the RNA strands. These RNA strands, in turn, can bind specifically to a DNA probe fixed to a small disposable electrode and provide a measurable current signal change.

Provided that here are no antibodies present, no RNA will be transcribed and no change in the current signal will be measured by the disposable electrode. If the sample contains influenza antibodies, then the machinery synthesizes RNA, which binds to the electrode, leading to a current signal. The reliable and inexpensive system is very specific and sensitive, and requires very small sample volumes, allowing it to be readily miniaturized for developing a portable and easy-to-use diagnostic tool. The system can also be adapted for detecting a wide variety of other antibodies.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.